China, Oct. 22 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Clinical Study Evaluating the Efficacy and Safety of 8 mg Aflibercept Using a Flexible Treat-and-Extend (T&E) Regimen in Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration (nAMD)'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600134826
Registration Time: 2026/10/21
Type: Observational study
Primary Sponsor: Qilu Hospital of Shandong University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338871
Published by HT Digital Content Services with permission from Health Daily Digest....